Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7425205 | 0.84 | SMYD3 (0.50) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL14225445 | 0.83 | MEN1 (0.44) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL2282033 | 0.81 | CPB2 (0.45) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL15775548 | 0.80 | MEN1 (0.43) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL21361934 | 0.80 | MEN1 (0.43) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL5730751 | 0.79 | SMYD3 (0.43) | SMYD3 | |
| SCHEMBL12458917 | 0.79 | KMT2A (0.42) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL16535011 | 0.79 | MEN1 (0.42) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| SCHEMBL20139133 | 0.79 | MEN1 (0.42) | MEN1KMT2AGRM2MAPK1SMYD3 | |
| Bicarbonate SCHEMBL7419537 | 0.79 | SMYD3 (0.46) | MEN1KMT2AGRM2MAPK1SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| CN-1894206-A | N-substituted N-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC (JP) | 2007-01-10 | — | — | CN | disclosed |
| EP-1694638-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2005-10-06 | — | — | US | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | MEN1 1376/4885KMT2A 2518/4885GRM2 1547/4885 |
| US-20050222146-A1 | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof | MMP13, MMP11, MMP1 | MEN1 1233/4885KMT2A 2446/4885GRM2 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.